FY24 sbir phase I- nvasive: unraveling the enigma of metastasis
Ended Purchase Order Awarded Last action
- Contract number
- 80NSSC24PB311
- Awardee
-
Encapsulate Inc. UEI JKQNFNJWF175
- Awarding agency
-
Shared Services Center
National Aeronautics and Space Administration
- Obligated
- $0
Award facts
- Contract value 0% obligated
- $156,494.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- 500 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Farmington, CT 06032, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $156,494 |
About this award
The U.S. government awarded a Phase I Small Business Innovation Research (SBIR) contract valued at $156,494 to Encapsulate Inc., a Farmington, Connecticut-based small disadvantaged business specializing in precision oncology and personalized cancer screening technologies. Awarded on August 7, 2024, with completion scheduled for February 6, 2025, this total small business set-aside contract is funded through the NASA Shared Services Center under a firm fixed-price arrangement. The contract supports the NVASIVE project, which applies artificial intelligence and machine learning methodologies to predict cancer metastasis using noninvasive techniques and microgravity research environments. Encapsulate Inc. is developing automated microfluidic biochip platforms integrated with bioreactors and 3D tumor models to enable personalized cancer treatment selection by testing patient-derived cancer cells against chemotherapy drugs prior to therapy initiation.
This Phase I award represents the initial stage of a multi-phase SBIR investment in Encapsulate Inc.'s precision oncology platform. The company has leveraged federal funding to address a significant healthcare challenge, as over 70 percent of cancer patients currently undergo ineffective chemotherapy through trial-and-error treatment methods. The technology targets a $2 billion domestic market in colorectal and pancreatic cancer treatment, with broader global market potential exceeding $30 billion. Encapsulate Inc.'s combined federal contract and grant investments across NASA and the National Science Foundation now exceed $5.3 million, reflecting sustained federal validation of the company's mission to reduce ineffective treatment cycles and lower overall healthcare costs through data-driven diagnostic innovation.
Quick answers
Who was awarded contract 80NSSC24PB311?
80NSSC24PB311 was awarded to Encapsulate Inc. by Shared Services Center (National Aeronautics and Space Administration) on August 7, 2024.
How much is contract 80NSSC24PB311 worth?
The government has obligated $0 on 80NSSC24PB311. Its current value, with exercised options, is $156,494.
Was contract 80NSSC24PB311 competed?
The government received 500 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award